A new report reveals more than 180 companies are actively developing over 200 PD-1 and PD-L1 inhibitors, a class of immunotherapies that boost the immune system to fight cancer. These drugs target various cancers including lung, bladder, liver, and endometrial cancers, with several in late-stage trials. Key players like Merck, Roche, and Pfizer are advancing promising candidates, while regulatory approvals and breakthrough designations signal strong growth potential. This expanding pipeline highlights ongoing innovation and competition in oncology treatments, promising improved patient outcomes and new market opportunities.
The Invesco S&P 500 Momentum ETF (SPMO) underwent a semi-annual reconstitution, resulting in 54 changes affecting about 40% of its portfolio. Apple and Merck were the largest additions, while Nvidia was removed despite a strong one-year gain of over ...
Moderna's shares surged 9% after its Phase 3 melanoma study was selected for a prestigious Presidential Symposium slot at the European Society for Medical Oncology congress. This high-profile placement signals strong confidence in the study's potenti...
Amgen and Merck both pay quarterly dividends and raise them annually, but Amgen offers a higher yield (2.6% vs. 2.29%) and has consistently raised dividends by about 6% annually. While Merck relies heavily on its Keytruda franchise, facing a looming ...
Pfizer has paused its annual dividend increase for the first time in over a decade, maintaining a quarterly payout of $0.43 throughout 2026. This pause comes despite a strong 6.2% dividend yield and solid adjusted earnings coverage, reflecting cautio...
Moderna's stock surged 6% to $154, extending a 137% gain over the past month driven by promising Phase 2b melanoma vaccine data presented at ASCO 2026. The data showed a 49% reduction in risk of recurrence or death when combining Moderna's intismeran...
